Roivant Sciences Ltd. Common Shares (ROIV) Stock Price

ROIVStock

$36.47+205.03%52W

Market Cap$26.34B

P/E—

PEG Ratio—

Div yield—

Beta1.11

ROIV Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)21.07%

Price vs S&P 500 (4W)4.39%

VGM Score38.12

Book Value / Share (Quarterly)$5.86

P/TBV (Annual)1.44x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)-48.73%

Cash Flow / Share (Quarterly)$-1.14

Price vs S&P 500 (YTD)55.60%

Gross Margin (TTM)81.21%

Net Profit Margin (TTM)-3534.96%

EPS (TTM)$-0.39

10-Day Avg Trading Volume5.58M

EPS Excl Extra (TTM)$-0.39

Revenue Growth (5Y)-19.08%

EPS (Annual)$-0.43

ROI (Annual)-6.62%

Gross Margin (Annual)84.44%

Net Profit Margin (5Y Avg)-782.33%

Cash / Share (Quarterly)$5.32

Revenue Growth QoQ (YoY)-33.55%

ROA (Last FY)-5.25%

Revenue Growth TTM (YoY)-67.58%

EBITD / Share (TTM)$-0.83

ROE (5Y Avg)-15.12%

Operating Margin (TTM)-7768.35%

Cash Flow / Share (Annual)$-1.05

P/B Ratio6.19x

P/B Ratio (Quarterly)6.02x

Net Income / Employee (Annual)$-399,700

EV / Revenue (TTM)3313.52x

Net Interest Coverage (TTM)-72.78x

ROA (TTM)-5.00%

EV / EBITDA (TTM)5.69x

EPS Incl Extra (Annual)$-0.43

Current Ratio (Annual)18.37x

Quick Ratio (Quarterly)16.72x

3-Month Avg Trading Volume5.82M

52-Week Price Return205.03%

Revenue / Employee (TTM)$10,000

Tangible BV / Share (Quarterly)$7.17

P/S Ratio (Annual)3172.62x

Asset Turnover (Annual)0.00x

52-Week High$37.97

Operating Margin (5Y Avg)-2020.10%

EPS Excl Extra (Annual)$-0.43

CapEx CAGR (5Y)7.19%

26-Week Price Return32.31%

Quick Ratio (Annual)18.37x

13-Week Price Return17.75%

Total Debt / Equity (Annual)0.00x

Current Ratio (Quarterly)16.72x

Enterprise Value$24.96B

Revenue / Share Growth (5Y)-19.31%

Asset Turnover (TTM)0.00x

Revenue / Employee (Annual)$11,000

Pretax Margin (Annual)-3203.12%

Cash / Share (Annual)$5.96

3-Month Return Std Dev35.21%

Gross Margin (5Y Avg)73.72%

Net Income / Employee (TTM)$-355,000

ROE (Last FY)-6.62%

Net Interest Coverage (Annual)-7.02x

EPS Basic Excl Extra (Annual)$-0.43

Receivables Turnover (TTM)4.67x

Total Debt / Equity (Quarterly)0.00x

EPS Incl Extra (TTM)$-0.39

Receivables Turnover (Annual)2.97x

ROI (TTM)-6.12%

P/S Ratio (TTM)3479.27x

Pretax Margin (5Y Avg)-1111.67%

Revenue / Share (Annual)$0.01

Tangible BV / Share (Annual)$7.23

Price vs S&P 500 (52W)186.72%

Year-to-Date Return67.56%

5-Day Price Return-2.70%

EPS Normalized (Annual)$-0.43

ROA (5Y Avg)-4.63%

Net Profit Margin (Annual)-3629.19%

Month-to-Date Return7.22%

Cash Flow / Share (TTM)$-1.62

EBITD / Share (Annual)$-0.72

Operating Margin (Annual)-6102.19%

LT Debt / Equity (Annual)0.07x

ROI (5Y Avg)-10.32%

LT Debt / Equity (Quarterly)0.06x

EPS Basic Excl Extra (TTM)$-0.39

P/TBV (Quarterly)1.51x

P/B Ratio (Annual)4.38x

Inventory Turnover (TTM)0.61x

Pretax Margin (TTM)-3848.65%

Book Value / Share (Annual)$6.28

Price vs S&P 500 (13W)14.95%

Beta1.11x

Revenue / Share (TTM)$0.01

ROE (TTM)-6.12%

52-Week Low$11.60

vGradeD

gGradeF

mGradeB

vgmGradeD

ROIV Earnings Surprise History

Q2 25-0.25est. -0.23

Q3 25-0.28est. -0.30

Q4 25-0.24est. -0.31

Q1 26-0.32est. -0.35

Q2 26-0.34est. -0.36

ROIV Analyst Recommendations

May 2026

Jun 2026

Jul 2026

Aug 2026

4.32

Industry Peers — Pharmaceuticals(571)

Symbol	Value Score	Growth Score	Momentum Score	Price
ROIVRoivant Sciences Ltd. Common Shares	D	F	B	$36.47
LLYEli Lilly & Co.	D	B	B	$1233.66
JNJJohnson & Johnson	D	C	B	$273.14
ABBVABBVIE INC.	D	C	B	$265.79
MRKMerck & Co., Inc.	D	C	A	$156.45
NVSNovartis AG	C	C	C	$159.98
AZNAstraZeneca PLC	C	B	C	$169.66
NVONovo-Nordisk A/S	B	C	C	$48.66
ABTAbbott Laboratories	C	C	B	$116.13
PFEPfizer Inc.	C	D	C	$28.57
VRTXVertex Pharmaceuticals Inc	D	C	B	$552.85
BMYBristol-Myers Squibb Co.	B	B	B	$67.92
SNYSanofi American Depositary Shares (Each representing one-half of one ordinary share)	B	C	C	$46.02
GSKGSK plc American Depositary Shares (Each representing two Ordinary Shares)	B	C	C	$52.07
REGNRegeneron Pharmaceuticals Inc	C	C	B	$833.56
TAKTakeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)	C	C	C	$18.35
TEVATeva Pharmaceutical Industries Limited American Depositary Shares	C	C	C	$38.10
ONCBeOne Medicines Ltd. American Depositary Shares	D	B	C	$376.37
RPRXRoyalty Pharma plc Class A Ordinary Shares	D	D	B	$62.07
ALNYAlnylam Pharmaceuticals, Inc.	D	A	D	$240.08
ZTSZOETIS INC.	B	C	D	$77.29
INSMInsmed, Inc.	F	A	C	$123.89
UTHRUnited Therapeutics Corp	C	C	C	$518.53
GMABGenmab A/S ADS	C	C	B	$34.36
VTRSViatris Inc. Common Stock	B	C	B	$16.72
JAZZJazz Pharmaceuticals, Inc.	B	C	B	$260.23
ASNDAscendis Pharma A/S Ordinary Share	D	A	C	$252.99
BBIOBridgeBio Pharma, Inc. Common Stock	F	A	B	$80.40
CORTCorcept Therapeutics Inc.	F	C	A	$123.57
BMRNBioMarin Pharmaceuticals Inc	C	C	C	$66.12
ARWRArrowhead Research Corporation	D	A	B	$88.88
ELANElanco Animal Health Incorporated Common Stock	C	B	B	$25.09
MDGLMadrigal Pharmaceuticals, Inc. Common Stock	D	A	C	$512.16
CYTKCytokinetics Inc.	F	D	B	$77.46
AXSMAxsome Therapeutics, Inc	D	B	C	$205.48
SMMTSummit Therapeutics Inc. Common Stock	F	—	D	$13.36
IONSIonis Pharmaceuticals, Inc. Common Stock	D	D	C	$63.57
ABVXAbivax SA American Depositary Shares	—	—	C	$117.93
RDYDr. Reddy's Laboratories Limited American Depositary Shares	D	D	C	$12.34
PRAXPraxis Precision Medicines, Inc. Common Stock	F	—	B	$368.02
NUVLNuvalent, Inc. Class A Common Stock	—	—	B	$123.96
PTGXProtagonist Therapeutics, Inc	F	B	A	$150.59
SYRESpyre Therapeutics, Inc. Common Stock	—	—	A	$107.36
CRNXCrinetics Pharmaceuticals, Inc.	F	A	A	$84.86
TGTXTG Therapeutics, Inc.	D	B	A	$55.42
ALKSAlkermes Inc. plc	D	C	B	$49.21
RYTMRhythm Pharmaceuticals, Inc. Common Stock	F	B	C	$113.35
ORKAOruka Therapeutics, Inc. Common Stock	F	—	A	$101.82
BLTEBelite Bio, Inc American Depositary Shares	—	—	B	$161.68
COGTCogent Biosciences, Inc. Common Stock	F	—	B	$36.80
TVTXTravere Therapeutics, Inc. Common Stock	F	B	A	$67.01

About Roivant Sciences Ltd. Common Shares

Roivant Sciences is a commercial-stage biopharmaceutical company with VTAMA (tapinarof), an approved treatment for plaque psoriasis, as its lead marketed product. The company maintains a pipeline of drug candidates across development stages including Batoclimab, Brepocitinib, Namilumab, and IMVT-1402. Roivant also incubates discovery-stage biotech companies and health technology platforms adjacent to its core pharmaceutical business.